Mineralocorticoid receptors in myocardial infarction

Hypertension

Volumn 54, Issue 6, 2009, Pages 1211-1212

  Stier, Charles T ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE; ALDOSTERONE SYNTHASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA CARBOLINE; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; HYDROCORTISONE; MIFEPRISTONE; MINERALOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR ANTAGONIST; OLMESARTAN; RECEPTOR BLOCKING AGENT; SPIRONOLACTONE; TEMPOL; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; BRAIN EDEMA; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN INJURY; DRUG RECEPTOR BINDING; ENZYME INHIBITION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HORMONE ACTION; HUMAN; IMMUNOSTIMULATION; INVERSE AGONISM; NONHUMAN; NOTE; PRIORITY JOURNAL; RECEPTOR BLOCKING; PATHOPHYSIOLOGY; PHYSIOLOGY;

HUMANS; MYOCARDIAL INFARCTION; RECEPTORS, MINERALOCORTICOID;

EID: 73349113223     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.140384     Document Type: Note

References (11)

1. Mihailidou AS, Le TYL, Mardini M, Funder JW. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension. 2009;54:1306-1312
2. Dorrance AM, Osborn HL, Grekin R, Webb RC. Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am J Physiol Regulatory Integrative Comp Physiol. 2001;281:R944-R950
3. Delcayre C, Silvestre J-S, Garnier A, Oubenaissa A, Cailmail S, Tatara E, Swynghedauw B, Robert V. Cardiac aldosterone production and ventricular remodeling. Kidney Int. 2000;57:1346-1351
4. Rebsamen MC, Perrier E, Gerber-Wicht C, Benitah J-P, Lang U. Direct and indirect effects of aldosterone on cyclooxygenase-2 and interleukin-6 expression in rat cardiac cells in culture and after myocardial infarction. Endocrinology. 2004;145:3135-3142
5. Ross EM. Pharmacodynamics: mechanisms of drug action and the relationship between drug concentraton and effect. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw Hill; 2008:20-41
6. Chun T-Y, Bloem L, Pratt JH. Spironolactone increases integrin /33 gene expression in kidney and heart muscle cells. Molec Cell Endocrinol. 2002;194:175-182
7. Quan ZY, Walser M, Hill GS. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int. 1992;41:326-333
8. Kawamura T, Yoshioka T, Bills T, Fogo A, Ichikawa I. Glucocorticoid activates glomerular antioxidant enzymes and protects glomeruli from oxidant injuries. Kidney Int. 1991;40:291-301
9. Chander PN, Rocha R, Ranaudo J, Singh G, Zuckerman A, Stier CT. Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP. J Am Soc Nephrol. 2003;14:1990-1997
10. Gomez-Sanchez EP, Ahmad N, Romero DG, Gomez-Sanchez CE. Origin of aldosterone in the rat heart. Endocrinology. 2004;145:4796-4802
11. Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al-Saadi N, Dechend R, Wellner M, Meiners S, Maser-Gluth C, Jeng AY, Webb RL, Luft FC, Muller DN. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation. 2005;111: 3087-3094 (Pubitemid 40847786)